7,082 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 7,082 shares of the biopharmaceutical company's stock, valued at approximately $213,000.

Several other large investors have also recently bought and sold shares of TGTX. Vanguard Group Inc. grew its holdings in shares of TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after purchasing an additional 209,190 shares in the last quarter. State Street Corp lifted its position in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after purchasing an additional 2,398,015 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock worth $38,212,000 after buying an additional 84,904 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of TG Therapeutics by 10.5% in the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company's stock worth $27,797,000 after buying an additional 87,679 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of TG Therapeutics by 7.5% during the 4th quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company's stock valued at $24,989,000 after buying an additional 57,996 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

Remove Ads

TG Therapeutics Trading Down 5.1 %

NASDAQ TGTX traded down $1.99 during trading on Friday, hitting $37.35. 3,137,631 shares of the company's stock traded hands, compared to its average volume of 3,083,830. The stock has a fifty day moving average of $35.27 and a two-hundred day moving average of $30.85. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The firm has a market cap of $5.87 billion, a P/E ratio of -373.46 and a beta of 2.13. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on TGTX. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.